Join us as we go over our top stories from the week:
Fred Hutchinson Cancer Research Center Collaborates with Alkermes plc to Conduct Clinical Trial for Novel Immuno-Oncology Drug Candidate. UC San Diego Moores Cancer Center Immunotherapy Clinic Reveals the Future is Now. Pancreatic Cancer Drug Developed by Stony Brook University Moves into Phase III Clinical Trials. Could Autism be an Autoimmune Disorder? Investigators at Beth Israel Deaconess Medical Center (BIDMC) Think Possibly. University of Minnesota Opens First-Ever U.S. Clinical Trial of Engineered iPSC-derived Cell Therapy for Blood Cancer. Odonate Therapeutics Announces Patient Enrollment Completion for CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer. Asia-focused Non-Invasive Colon Detection Technology to be Commercialized by Alibaba-backed Digital Health Venture. Privately-Held Segal Clinical Supports Usona Institute’s PSIL201 Clinical Trial Testing the Use of Psilocybin for Major Depression. ASDS Awards Eight Clinical and Cosmetic Research Grants. $14.6 Million in Awards Granted to 43 Multiple Sclerosis Projects by National MS Society. Dynamic University of Rio Grande do Norte Investigator Headed to University of Auckland to Discuss Research into Ayahuasca for Antidepressant Properties. Looking for Earliest Stages of Cancer Leads to Radically Innovative Research by International Alliance. Health Systems Increasingly Step into Clinical Trials Participation: The PIER Consortium™ Example. i-Mab Biopharma Expands its Study of MOR202 for Multiple Myeloma Patients in Dozens of Sites in China. La Jolla Institute of Immunology Adopts Seqster Platform to Support Study Pursuing Personalized Asthma Treatments as part of $6.9M NHLBI Study. .University of Colorado Anschutz Medical Campus Awarded $4M as Part of NIH Commercialization Hub Program called REACH.